¼¼°èÀÇ µ¿¹°¿ë ÀǾàǰ ½ÃÀå
Veterinary Medicines
»óǰÄÚµå : 1773939
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 466 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

µ¿¹°¿ë ÀǾàǰ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 752¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 485¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â µ¿¹°¿ë ÀǾàǰ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 7.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 752¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ »ý»êµ¿¹°Àº CAGR 9.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 508¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ý·Áµ¿¹° ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 132¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 12.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ µ¿¹°¿ë ÀǾàǰ ½ÃÀåÀº 2024³â¿¡ 132¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 162¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 12.1%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.7%¿Í 7.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 5.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ µ¿¹°¿ë ÀǾàǰ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

µ¿¹° ÀÇ·á´Â Çö´ë µ¿¹° °Ç°­ °ü¸®ÀÇ ÇÙ½ÉÀÌ µÇ°í Àִ°¡?

¼öÀÇÇÐÀº µ¿¹°ÀÇ Ä¡·á¿Í °ü¸®¶ó´Â ÀüÅëÀûÀÎ ¿ªÇÒÀ» ³Ñ¾î °øÁߺ¸°Ç, ½Ä·® ¾Èº¸, ³ª¾Æ°¡ »ý¹° ÀÇÇÐÀÇ Çõ½ÅÀ» µÞ¹ÞħÇÏ´Â Áß¿äÇÑ ÃàÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¼¼°è ¼öÀÇÇÐ ½ÃÀåÀº Áø´ÜÇÐ, Ä¡·áÇÐ, Á¤¹Ð µ¿¹° ÀÇ·áÀÇ ¹ßÀü¿¡ ÈûÀÔ¾î ¿ªµ¿ÀûÀ¸·Î º¯È­Çϰí ÀÖ½À´Ï´Ù. Àμö°øÅëÀü¿°º´(µ¿¹°¿¡¼­ »ç¶÷À¸·Î Àü¿°µÇ´Â Áúº´)¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó °¢±¹ Á¤ºÎ¿Í ±¹Á¦±â±¸´Â °¨½Ã ¹× °ü¸® ü°è¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó µ¿¹°¿ë ÇコÄɾî ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ°¡ ÃËÁøµÇ°í, ¿¹¹æ ¹× Ä¡·á¿ë µ¿¹°¿ë ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¡ÃàÀÇ °Ç°­Àº °æÁ¦ÀûÀ¸·Îµµ Àü·«ÀûÀ¸·Î Áß¿äÇÑ Àǹ̸¦ °®°Ô µÇ¾ú½À´Ï´Ù. ¿ìÀ¯, À°·ù, °è¶õ°ú °°Àº µ¿¹°¼º Á¦Ç°ÀÇ Ç°Áú°ú »ý»ê·®Àº È¿°úÀûÀÎ ¼öÀÇÇÐ Ä¡·á¿Í Á÷°áµÇ±â ¶§¹®ÀÔ´Ï´Ù. Á¶·ùÀÎÇ÷翣ÀÚ, ¾ÆÇÁ¸®Ä« µÅÁö ÄÝ·¹¶ó, ±¸Á¦¿ª°ú °°Àº Àü¿°º´ÀÇ È®»êÀº Àü ¼¼°è Ãà»ê ºÎ¹®¿¡ Å« ¼Õ½ÇÀ» °¡Á®¿Ô°í, ¼öÀÇÇÐÀû °³ÀÔÀÇ Á߿伺À» ´õ¿í °­Á¶Çϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ ¹Ý·Áµ¿¹°ÀÇ Àΰ£È­´Â ¼¼°èÀûÀÎ Ãß¼¼·Î ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÌ °í±Þ Ä¡·á¿Í ¿µ¾ç º¸ÃæÁ¦¿¡ ´õ ¸¹Àº ºñ¿ëÀ» ÁöÃâÇϸ鼭 ¹Ý·Áµ¿¹° ºÐ¾ßÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, FDA, EMA, USDA¿Í °°Àº ±ÔÁ¦ ±â°üµµ ÀǾàǰ ½ÂÀÎÀ» °¡¼ÓÈ­ÇÏ°í ±ÔÁ¦ ¸íÈ®¼ºÀ» Çâ»ó½ÃÄÑ ÀÌ ºÐ¾ßÀÇ ¿¬±¸ °³¹ß ¼º°ú¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ¿¬±¸°³¹ß ¼º°ú¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼öÀÇÇаú ÀÎüÀÇÇÐÀÇ À¶ÇÕÀÌ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ƯÈ÷ Áø´Ü, ¸ð´ÏÅ͸µ, ¿ªÇÐÀ» °øÀ¯ÇÏ´Â »ýŰ迡¼­ µ¿¹°, Àΰ£, ȯ°æÀÇ °Ç°­À» ¿¬°áÇÏ´Â ¿øÇコ Á¢±Ù¹ýÀÌ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù.

µ¿¹°¿ë ÀǾàǰ°ú »ý¹°ÇÐÀû Á¦Á¦ÀÇ Çõ½ÅÀº ½ÃÀå »óȲÀ» ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

±â¼ú Çõ½ÅÀÇ ¹°°áÀº ƯÈ÷ ÀǾàǰ°ú »ý¹°ÇÐÀû Á¦Á¦ ºÐ¾ß¿¡¼­ ¼öÀÇÇÐ ÀǷḦ À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ÀǾàǰÀÇ ¹ßÀüÀº Àå½Ã°£ ÀÛ¿ëÇÏ´Â ÁÖ»çÁ¦, ¹æÃâ Á¦¾îÇü ¾à¹°Àü´Þ ½Ã½ºÅÛ, Á¾ ƯÀÌÀû ¾àµ¿Çп¡ ¸ÂÃá »õ·Î¿î Ç×±ÕÁ¦ °³¹ß µî Á¡Á¡ ´õ Àΰ£ÀÇ ÀÇÇÐ ¹ßÀüÀ» ¸ð¹æÇϰí ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦, ƯÈ÷ ¹é½Å°ú ´ÜŬ·ÐÇ×ü´Â Æø¹ßÀûÀÎ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖÀ¸¸ç, DNA ±â¹Ý ¹× º¤ÅÍ ±â¹Ý ¹é½ÅÀº ´õ ³ªÀº ¸é¿ª¿ø¼º ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÏ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ¸ç ´õ ¿À·¡ Áö¼ÓµÇ´Â ¸é¿ª·ÂÀ» Á¦°øÇϱâ À§ÇØ ºü¸£°Ô °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ¾çµ· ¹× ¾ç°è »ê¾÷¿¡¼­´Â ³óÀå °íÀ¯ÀÇ º´¿øÃ¼ ±ÕÁÖ¸¦ ±â¹ÝÀ¸·Î ¸ÂÃãÇü ¹æ¾î¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ÀÚ°¡ ¹é½ÅÀÌ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±âÁ¸ ±¸ÃæÁ¦ ¹× ¿ÜºÎ ±â»ýÃæ ±¸Á¦¾à¿¡ ´ëÇÑ ±â»ýÃæÀÇ ³»¼ºÀÌ Áõ°¡ÇÔ¿¡ µû¶ó AI¿Í ¸Ó½Å·¯´×À» Ȱ¿ëÇÏ¿© ¹æ´ëÇÑ ¼öÀÇÇÐ µ¥ÀÌÅͼ¼Æ®¸¦ ºÐ¼®Çϰí Ç¥Àû Ä¡·á¹ýÀ» ¼³°èÇÏ¿© ÀÓ»ó °á°ú¸¦ ÃÖÀûÈ­ÇÏ´Â Ç×±â»ýÃæÁ¦ Çõ½ÅÀÌ µîÀåÇϰí ÀÖ½À´Ï´Ù. À¯±â³ó Ãà»ê°ú ¹Ý·Áµ¿¹°ÀÇ °Ç°­¿¡ ´ëÇÑ °ü½É Áõ°¡¿¡ ÈûÀÔ¾î ¿µ¾çÁ¦ ¹× ÇÁ·Î¹ÙÀÌ¿Àƽ½º Á¦Á¦µµ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ý·Áµ¿¹°ÀÇ ±âÈ£¼ºÀ» °³¼±ÇÑ °æÇÇ ÆÐÄ¡ ¹× °æ±¸ Çöʾװú °°Àº Çõ½ÅÀûÀÎ Àü´Þ Ç÷§Æû¿¡ ´ëÀÀÇϱâ À§ÇØ ±ÔÁ¦ °æ·Î°¡ ÁøÈ­Çϰí ÀÖÀ¸¸ç, Zoetis, Elanco, Boehringer Ingelheim, Merck Animal Health µî °ú °°Àº ÁÖ¿ä ±â¾÷µéÀº »õ·Î¿î Ä¡·áÁ¦¸¦ È®º¸ÇÏ°í ´õ ³ÐÀº ½ÃÀå Á¡À¯À²À» È®º¸Çϱâ À§ÇØ ¿¬±¸°³¹ß°ú Àü·«Àû Àμö¸¦ µÎ ¹è·Î ´Ã¸®°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ÙÀÌ¿ÀÀǾàǰ ºÕÀº ÀÓ»ó½ÃÇè°ú »ó¾÷Àû Ãâ½Ã¸¦ °¡¼ÓÈ­ÇÏ´Â ¼öÀÇÇÐ Àü¹® CRO(ÀÓ»ó½ÃÇè¼öʱâ°ü)ÀÇ ÃâÇöÀ¸·Î ÀÎÇØ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦¿Í ÀúºÐÀÚ Á¦Á¦´Â °¡°Ý Ã¥Á¤, ƯÇã ¿ªÇÐ, Åõ¿© ÇÁ·ÎÅäÄÝ µîÀÇ Ãø¸é¿¡¼­ Â÷À̰¡ ÀÖ¾î µ¿¹°¿ë ÀǾàǰ ¼¼°è ½ÃÀå¿¡ »õ·Î¿î º¹À⼺°ú ±âȸ¸¦ ´õÇϰí ÀÖ½À´Ï´Ù.

µðÁöÅÐ ±â¼ú°ú ÷´Ü Áø´ÜÀÌ ¼öÀÇÇÐ Áø·á Çü¼º¿¡ ¹ÌÄ¡´Â ¿ªÇÒÀº?

µðÁöÅÐ ±â¼ú°ú ÷´Ü Áø´ÜÇÐÀÌ ¼öÀÇÇп¡ µµÀԵǸ鼭 µ¿¹°ÀÇ °Ç°­À» ¸ð´ÏÅ͸µÇϰí, Áø´ÜÇϰí, °ü¸®ÇÏ´Â ¹æ½ÄÀÌ ±Ùº»ÀûÀ¸·Î ¹Ù²î¾ú½À´Ï´Ù. °¡Ãà ¹× ¹Ý·Áµ¿¹°¿ë ¿þ¾î·¯ºí ±â±â´Â ü¿Â, ¿îµ¿ ÆÐÅÏ, ¼·½Ä Çൿ, ºÐ¸¸ Áֱ⠵î Áß¿äÇÑ »ýü µ¥ÀÌÅ͸¦ ½Ç½Ã°£À¸·Î ¼öÁýÇÒ ¼ö ÀÖ°Ô µÇ¾î Áúº´°ú Çൿ ÀÌ»óÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, IoT Áö¿ø ¼¾¼­¿Í Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀ» Ȱ¿ëÇÑ Á¤¹Ð Ãà»êÀº º¸´Ù È¿À²ÀûÀÎ °¡Ãà °ü¸®¸¦ ÃËÁøÇϰí È¿À²ÀûÀÎ ¿ì±º °ü¸®¸¦ ÃËÁøÇϰí Áúº´ Àü¿°À» °¨¼Ò½Ã۰í ÀÖ½À´Ï´Ù. ÇѶ§ Æ´»õ½ÃÀåÀ̾ú´ø ¼öÀÇ ¿ø°ÝÀÇ·á´Â COVID-19 ÀÌÈÄ ÁÖ·ù·Î ¹Þ¾Æµé¿©Á® ¼öÀǻ簡 Á÷Á¢ ¹æ¹®ÇÏÁö ¾Ê°íµµ ¿ø°ÝÀ¸·Î »ó´ãÇϰí, ó¹æÇϰí, ¸¸¼ºÁúȯÀ» ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. RT-PCR, ELISA, Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS)À» Æ÷ÇÔÇÑ ºÐÀÚÁø´Ü¹ýÀº ±× ¼Óµµ, ¹Î°¨µµ, ƯÀ̼ºÀ¸·Î ÀÎÇØ ±âÁ¸ÀÇ ¹Ì»ý¹°ÇÐÀû ¹æ¹ýÀ» ´ëüÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â »õ·Î¿î Àμö°øÅëÀü¿°º´ÀÇ À§ÇùÀ» ½Äº°ÇÏ°í °³º°È­µÈ Ä¡·á °èȹÀ» ¼ö¸³ÇÏ´Â µ¥ ¸Å¿ì À¯¿ëÇÏ´Ù´Â °ÍÀÌ ÀÔÁõµÇ°í ÀÖ½À´Ï´Ù. ·¦¿ÂĨ Àåºñ´Â ¼Ò±Ô¸ð Áø·á¼Ò³ª À̵¿½Ä µ¿¹°º´¿ø¿¡¼­µµ ÇöÀå Áø´ÜÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¼öÀÇÇÐ ÀüÀڰǰ­±â·Ï(EHR)°ú ºÐ¼® ´ë½Ãº¸µåÀÇ ÅëÇÕÀº ÀÓ»óÀÇ¿¡°Ô µ¥ÀÌÅÍ ±â¹Ý ÀλçÀÌÆ®¸¦ Á¦°øÇϰí, »ç·Ê °ü¸®, Ä¡·á È¿°ú ÃßÀû, ¾à¹° »ç¿ë °¨»ç¸¦ °£¼ÒÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý Áø·á °ü¸® ¼ÒÇÁÆ®¿þ¾î´Â Àç°í °ü¸®, Àκ¸À̽º ¹ßÇà, ȯÀÚ ÃßÀû µîÀÇ °ü¸® ¾÷¹«¸¦ ´õ¿í ÀÚµ¿È­Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, µ¿¹°º´¿øÀº ´õ ¶È¶ÈÇϰí, ´õ ºü¸£°í, ´õ ´Éµ¿ÀûÀ¸·Î º¯È­Çϰí ÀÖÀ¸¸ç, µ¿¹° º¸È£ÀÚ¿Í ½Äǰ »ý»êÀÚÀÇ ³ô¾ÆÁø ±â´ë¿¡ ºÎÀÀÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀΰøÁö´ÉÀº ¹æ»ç¼± ¹× º´¸®Á¶Á÷ÇÐ ¿µ»ó ÀÎ½Ä µµ±¸¸¦ ÅëÇØ Áø´Ü Á¤È®µµ¸¦ ³ôÀ̰í ÇØ¼® ½Ã°£À» ´ÜÃàÇÏ´Â µ¿½Ã¿¡ Áø´Ü Á¤È®µµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µðÁöÅÐ Àο¡ÀÌºí·¯´Â Ä¡·á °á°ú¸¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó Àü ¼¼°èÀûÀ¸·Î ¾çÁúÀÇ ¼öÀÇÇп¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

µ¿¹°¿ë ÀǾàǰ ¼¼°è ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ..

µ¿¹°¿ë ÀǾàǰ ½ÃÀåÀÇ ¼ºÀå ±ËÀûÀº ±â¼ú, Àα¸Åë°è, ±ÔÁ¦, ÃÖÁ¾»ç¿ëÀÚ ¿µ¿ª¿¡ °ÉÃÄ ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ ¿©·¯ ½ÃÀå ÃËÁø¿äÀο¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀº Àü ¼¼°èÀûÀ¸·Î ´Ü¹éÁúÀÌ Ç³ºÎÇÑ »ç·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â °¡Ãà °³Ã¼¼ö¸¦ Áõ°¡½ÃŰ°í ½Äǰ ¾ÈÀü°ú ¼öÀ²À» À§ÇØ µ¿¹°ÀÇ °Ç°­À» ÃÖÀûÀ¸·Î À¯ÁöÇØ¾ß ÇÑ´Ù´Â ¾Ð·ÂÀ» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹° »çÀ°Àº ƯÈ÷ µµ½Ã Áö¿ª°ú °í¼ÒµæÃþ¿¡¼­ ±ÞÁõÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿¹¹æ Ä¡·á, °Ç°­º¸Á¶Á¦, °í±Þ ¼öÀÇÇÐÀû óġ¿¡ ´ëÇÑ ÁöÃâ Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ±â¼ú Ãø¸é¿¡¼­´Â ÷´Ü Áø´Ü Ç÷§Æû°ú ÀÚµ¿ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ µµÀÔÀ¸·Î Áúº´ °¨½Ã ¹× Á¶±â °³ÀÔÀÇ ¼º°ú°¡ Å©°Ô Çâ»óµÇ¾úÀ¸¸ç, mRNA ±â¹Ý ¹× º¤ÅÍ ±â¹Ý Ç÷§ÆûÀ» Æ÷ÇÔÇÑ ¹é½Å ±â¼úÀÇ Çõ½ÅÀ¸·Î À¯Ç༺ ¹× ½ÅÈï Áúº´¿¡ ´ëÇÑ ½Å¼ÓÇÑ ¿¹¹æ Á¢Á¾ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. °¡´ÉÄÉ Çß½À´Ï´Ù. Àΰ£°ú µ¿¹° ¸ðµÎ¿¡¼­ Ç×±ÕÁ¦ ³»¼º(AMR)ÀÌ ±¤¹üÀ§ÇÏ°Ô ¹ß»ýÇϸ鼭 Â÷¼¼´ë Ç×±ÕÁ¦ ¹× ûÁö±â ÇÁ·Î±×·¥ °³¹ßÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú°í, ÀÌ´Â ÀǾàǰ Çõ½ÅÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©ÀÇ º¯È­, ƯÈ÷ ºÏ¹Ì¿Í À¯·´ÀÇ ½ÂÀÎ ÀýÂ÷ °£¼ÒÈ­·Î ÀÎÇØ »õ·Î¿î Ä¡·áÁ¦°¡ ½ÃÀå¿¡ Ãâ½ÃµÇ´Â ½Ã°£ÀÌ ´ÜÃàµÇ°í ÀÖ½À´Ï´Ù. ³ó¾÷ °ü·Ã ±â¾÷µéÀº »ç¸Á·üÀ» ³·Ãß°í Á¦Ç° ÃßÀû¼ºÀ» °³¼±Çϱâ À§ÇØ °ø±Þ¸Á¿¡ ¼öÀÇÇÐ ¼­ºñ½º¸¦ ÅëÇÕÇÏ´Â Ãß¼¼°¡ °­È­µÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ¼­ºñ½º ¹× °Ç°­ °ü¸® µµ±¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °¡Ãà ¹«¿ªÀÇ ¼¼°èÈ­´Â ±¹Á¦ ½Äǰ ¾ÈÀü ±âÁذú ÇÔ²² ¹«º´ Áõ¸í°ú ¼öÀÇ»ç ¸ð´ÏÅ͸µÀÇ Á߿伺À» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¾÷Çü µ¿¹°º´¿ø üÀÎ ¹× µ¿¹°º´¿øÀÇ µîÀåÀº Áø·á Á¦°ø ¸ðµ¨À» °ø½ÄÈ­ÇÏ¿© ±Ô¸ðÀÇ °æÁ¦¿Í ¼­ºñ½º Á¦°øÀ» °­È­ÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹° º¸Çè °¡ÀÔ·üµµ ²ÙÁØÈ÷ »ó½ÂÇϰí ÀÖÀ¸¸ç, ƯÈ÷ ½ÅÈï °æÁ¦±¹¿¡¼­ °í°¡ÀÇ Ä¡·á¸¦ º¸´Ù ½±°Ô Á¢ÇÒ ¼ö ÀÖ°Ô µÇ¾î °í±Þ µ¿¹° ÀÇ·á ¼­ºñ½ºÀÇ µµÀÔÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ Çൿ º¯È­, ±â¼ú Çõ½Å ÆÄÀÌÇÁ¶óÀÎ, »ê¾÷ ÅëÇÕ, Á¤Ã¥ °³Çõ¿¡ ±â¹ÝÇÑ ÀÌ·¯ÇÑ »óÈ£ ¿¬°üµÈ ¹ßÀüÀº ¸ðµÎ µ¿¹°¿ë ÀǾàǰ ¼¼°è ½ÃÀåÀÇ Áö¼Ó°¡´ÉÇÑ ¼ºÀåÀ» ÃËÁøÇÏ´Â °­·ÂÇÑ »ýŰ踦 ±¸ÃàÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

µ¿¹° À¯Çü(»ý»êµ¿¹°, ¹Ý·Áµ¿¹°), Á¦Ç°(»ý¹°ÇÐÀû Á¦Á¦, ÀǾàǰ, ¾à¿ë »ç·á÷°¡¹°), Åõ¿© °æ·Î(°æ±¸, ÁÖ»ç, ±¹¼Ò, ±âŸ °æ·Î), À¯Åë ä³Î(µ¿¹° º´¿ø ¹× Ŭ¸®´Ð, E-Commerce, ¿ÀÇÁ¶óÀÎ ¼Ò¸ÅÁ¡, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Veterinary Medicines Market to Reach US$75.2 Billion by 2030

The global market for Veterinary Medicines estimated at US$48.5 Billion in the year 2024, is expected to reach US$75.2 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Production Animals, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$50.8 Billion by the end of the analysis period. Growth in the Companion Animals segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.2 Billion While China is Forecast to Grow at 12.1% CAGR

The Veterinary Medicines market in the U.S. is estimated at US$13.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.2 Billion by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Veterinary Medicine Market - Key Trends & Drivers Summarized

Is Veterinary Medicine Becoming the Linchpin of Modern Animal Healthcare?

Veterinary medicine has evolved far beyond its traditional role of animal treatment and care, now emerging as a critical pillar supporting public health, food security, and even biomedical innovation. The global veterinary medicine market is undergoing a dynamic transformation driven by advances in diagnostics, therapeutics, and precision animal health. With increasing awareness around zoonotic diseases-where pathogens jump from animals to humans-governments and international agencies are reinforcing surveillance and control mechanisms. This has pushed investments in veterinary healthcare infrastructure and sparked a surge in demand for both preventive and therapeutic veterinary drugs. Moreover, livestock health has taken on strategic economic significance, as the quality and yield of animal-based products such as milk, meat, and eggs are directly linked to effective veterinary care. The rising prevalence of infectious diseases like avian influenza, African swine fever, and foot-and-mouth disease has led to significant losses in the global animal agriculture sector, further emphasizing the criticality of veterinary interventions. Simultaneously, pet humanization has become a global trend, with pet owners willing to spend more on advanced treatment and nutritional supplements, driving growth in the companion animal segment. Regulatory agencies like the FDA, EMA, and USDA are also accelerating drug approvals and improving regulatory clarity, further boosting R&D outcomes in the sector. In addition, there is increasing convergence between veterinary and human medicine, particularly in the One Health approach that links animal, human, and environmental health within a shared ecosystem of diagnostics, surveillance, and epidemiology.

How Is Innovation in Veterinary Pharmaceuticals and Biologics Transforming the Market Landscape?

A wave of innovation is reshaping veterinary medicine, especially within the pharmaceutical and biologics sectors. Pharmaceutical advancements are increasingly mimicking human medical breakthroughs, with the development of long-acting injectables, controlled-release drug delivery systems, and novel antimicrobial agents tailored to species-specific pharmacokinetics. Biologics, particularly vaccines and monoclonal antibodies, are experiencing explosive growth. DNA-based and vector-based vaccines are under rapid development, offering better immunogenic profiles and longer-lasting immunity with minimal side effects. Autogenous vaccines are gaining traction, especially in swine and poultry industries, enabling tailored protection based on farm-specific pathogen strains. Moreover, antiparasitic innovations have emerged in response to rising resistance among parasites to traditional anthelmintics and ectoparasiticides. Companies are increasingly utilizing AI and machine learning to analyze massive veterinary datasets to design targeted therapies and optimize clinical outcomes. Nutraceuticals and probiotic formulations have also gained popularity, driven by the rise in organic livestock farming and pet wellness. Further, regulatory pathways are evolving to accommodate innovative delivery platforms such as transdermal patches and oral suspensions with improved palatability for companion animals. Major players like Zoetis, Elanco, Boehringer Ingelheim, and Merck Animal Health are doubling down on R&D and strategic acquisitions to secure novel therapeutics and capture wider market share. This biopharmaceutical boom is also aided by the emergence of dedicated veterinary CROs (Contract Research Organizations), which are expediting clinical trials and commercial rollouts. The differentiation between biologics and small molecules in terms of pricing, patent dynamics, and administration protocols is adding new layers of complexity and opportunity to the global veterinary medicine market.

What Role Do Digital Technologies and Advanced Diagnostics Play in Shaping Veterinary Practice?

The infusion of digital technologies and advanced diagnostics into veterinary medicine has fundamentally altered how animal health is monitored, diagnosed, and managed. Wearable devices for livestock and pets are now capable of capturing vital biometric data in real time-such as body temperature, movement patterns, feeding behavior, and calving cycles-enabling early detection of illness and behavioral anomalies. Precision livestock farming, powered by IoT-enabled sensors and cloud computing, is fostering more efficient herd management and reducing disease transmission. Veterinary telemedicine, once a niche service, has gained mainstream acceptance post-COVID-19, allowing veterinarians to consult remotely, prescribe treatments, and monitor chronic conditions without physical visits. This has been particularly impactful in remote or underserved rural areas. Molecular diagnostics, including RT-PCR, ELISA, and next-generation sequencing (NGS), are rapidly replacing traditional microbiological techniques due to their speed, sensitivity, and specificity. These tools are proving invaluable in identifying emerging zoonotic threats and tailoring individualized treatment plans. Lab-on-a-chip devices are making point-of-care diagnostics feasible, even for small clinics and mobile veterinary units. Integration of veterinary electronic health records (EHRs) with analytics dashboards is offering clinicians data-driven insights, helping streamline case management, treatment efficacy tracking, and drug usage auditing. Cloud-based practice management software is further automating administrative tasks such as inventory, billing, and patient tracking. As a result, veterinary practices are becoming smarter, more responsive, and increasingly proactive, aligning well with the growing expectations of animal owners and food producers alike. Additionally, artificial intelligence is enabling image recognition tools for radiology and histopathology, improving diagnostic accuracy while reducing interpretation timeframes. These digital enablers are playing a pivotal role in not just improving outcomes but also expanding access to quality veterinary care worldwide.

The Growth In The Global Veterinary Medicine Market Is Driven By Several Factors…

The upward trajectory of the veterinary medicine market is underpinned by a multitude of well-defined, market-specific drivers spanning technological, demographic, regulatory, and end-user domains. A primary catalyst is the intensifying demand for protein-rich diets globally, which is increasing livestock populations and creating heightened pressure to maintain optimal animal health for food safety and yield. Companion animal ownership is also witnessing a boom, especially in urban and high-income demographics, leading to increased expenditure on preventive care, wellness supplements, and advanced veterinary procedures. On the technology front, the adoption of advanced diagnostic platforms and automated monitoring systems has significantly improved disease surveillance and early intervention outcomes. Innovations in vaccine technology, including mRNA-based and vector-based platforms, have enabled rapid immunization against endemic and emerging diseases. The widespread emergence of antimicrobial resistance (AMR) in both humans and animals is compelling the development of next-generation antimicrobials and stewardship programs, further pushing drug innovation. Shifts in regulatory frameworks, particularly streamlined approval processes in North America and Europe, are enabling faster time-to-market for novel therapeutics. Agribusinesses are increasingly integrating veterinary services within supply chains to reduce mortality and improve product traceability, spurring demand for services and health management tools. The globalization of livestock trade, along with international food safety norms, has elevated the importance of disease-free certification and veterinary oversight. Moreover, the rise of corporate veterinary chains and animal hospitals is formalizing care delivery models, enabling economies of scale and enhanced service delivery. Pet insurance uptake is also rising steadily, especially in developed economies, making costly treatments more accessible and further encouraging the adoption of premium veterinary services. All these interconnected developments-rooted in shifting consumer behaviors, innovation pipelines, industry consolidation, and policy reform-are creating a powerful ecosystem conducive to sustained growth in the global veterinary medicine market.

SCOPE OF STUDY:

The report analyzes the Veterinary Medicines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Animal Type (Production Animals, Companion Animals); Product (Biologics, Pharmaceuticals, Medicated Feed Additives); Administration Route (Oral, Injectable, Topical, Other Routes); Distribution Channel (Veterinary Hospitals & Clinics, E-Commerce, Offline Retail Stores, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â